SCHEMBL15710769

SCHEMBL15710769

CCN(CC)CCCC(C(=O)O)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SIGMAR1 Q99720 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ LMNA P02545 3/20 0.40
▸ CYP2D6 P10635 2/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ PAOX Q6QHF9 1/20 0.39
▸ CYP3A4 P08684 2/20 0.39
▸ MAPT P10636 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ CHRM1 P11229 2/20 0.37
▸ CHRM3 P20309 2/20 0.37
▸ CHRM2 P08172 1/20 0.37
▸ CHRM4 P08173 1/20 0.37
▸ NPSR1 Q6W5P4 2/20 0.37
▸ GAA P10253 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ KDM5A P29375 1/20 0.36
▸ KDM4C Q9H3R0 1/20 0.36
▸ AKR1A1 P14550 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15711008 0.98 SIGMAR1 (0.41) SIGMAR1ALDH1A1LMNACYP2D6CYP1A2
SCHEMBL17102940 0.93 SIGMAR1 (0.50) SIGMAR1ALDH1A1LMNACYP2D6CYP1A2
Water SCHEMBL28622482 0.91 SIGMAR1 (0.48) SIGMAR1ALDH1A1LMNACYP2D6CYP1A2
Hydrochloric Acid SCHEMBL28600382 0.91 SIGMAR1 (0.48) SIGMAR1ALDH1A1LMNACYP2D6CYP1A2
SCHEMBL15515280 0.86 CHRM1 (0.39) SIGMAR1ALDH1A1LMNACYP2D6CYP1A2
Ethylenediamine SCHEMBL19197826 0.85 SIGMAR1 (0.43) SIGMAR1ALDH1A1LMNACYP2D6CYP1A2
SCHEMBL30131273 0.85 SIGMAR1 (0.43) SIGMAR1ALDH1A1LMNACYP2D6CYP1A2
SCHEMBL27903555 0.84 DRD3 (0.39) MAPTCHRM1CHRM3KDM5AKDM4C
Putrescine SCHEMBL19198229 0.83 GSR (0.44) SIGMAR1ALDH1A1LMNACYP2D6CYP1A2
SCHEMBL19198172 0.83 SIGMAR1 (0.42) SIGMAR1ALDH1A1LMNACYP2D6CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2740738-B1 PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASE, PREPARATION METHODS AND USES THEREOF BEIJING FSWELCOME TECH DEVELOPMENT CO LTD (CN) 2018-03-28 — — EP claimed
EP-2740738-A1 PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASE, PREPARATION METHODS AND USES THEREOF Beijing FSwelcome Technology Development Co., Ltd. (CN) 2014-06-11 — — EP claimed
US-20140142079-A1 PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASES, PREPARATION METHOD AND USE THEREOF BEIJING FSWELCOME TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2014-05-22 — — US claimed
EP-2740738-B1 PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASE, PREPARATION METHODS AND USES THEREOF BEIJING FSWELCOME TECH DEVELOPMENT CO LTD (CN) 2018-03-28 — — EP disclosed
EP-2740738-B1 PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASE, PREPARATION METHODS AND USES THEREOF BEIJING FSWELCOME TECH DEVELOPMENT CO LTD (CN) 2018-03-28 — — EP disclosed
CN-103732601-B The one class treatment platinum compounds of cell proliferation disorders, its preparation method and application 北京市丰硕维康技术开发有限责任公司 2016-06-22 — — CN disclosed
US-9138421-B2 Platinum compounds for treating cell proliferative diseases, preparation method and use thereof BEIJING FSWELCOME TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2015-09-22 — — US disclosed
EP-2740738-A1 PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASE, PREPARATION METHODS AND USES THEREOF Beijing FSwelcome Technology Development Co., Ltd. (CN) 2014-06-11 — — EP disclosed
US-20140142079-A1 PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASES, PREPARATION METHOD AND USE THEREOF BEIJING FSWELCOME TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2014-05-22 — — US disclosed
US-20140142079-A1 PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASES, PREPARATION METHOD AND USE THEREOF BEIJING FSWELCOME TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2014-05-22 — — US disclosed
CN-102863474-A Platinum compounds for treating cell proliferative diseases and preparation method and application thereof CHEN XIAOPING 2013-01-09 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140142079-A1 PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASES, PREPARATION METHOD AND USE THEREOF PCNA, POLI, MKI67 SIGMAR1 4273/4885ALDH1A1 406/4885LMNA 1487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback